Search

Your search keyword '"Dallio M."' showing total 277 results

Search Constraints

Start Over You searched for: Author "Dallio M." Remove constraint Author: "Dallio M."
277 results on '"Dallio M."'

Search Results

2. OC.11.2: RED CELL DISTRIBUTION WIDTH (RDW) TO PLATELET RATIO (RDW/PLT RATIO) ACCURATELY PREDICTS 7-YEAR DECOMPENSATION AND MODALITIES OF DISEASE PROGRESSION IN COMPENSATED ADVANCED CHRONIC LIVER DISEASE: A PRELIMINARY OBSERVATION [THE REPLAY STUDY]

3. T.07.1: PREVALENCE OF DYSGEUSIA IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE (ACLD), RELATIONSHIP WITH THE LIVER-DISEASE PROGRESSION STATUS, AND IMPACT ON MALNUTRITION-SARCOPENIA-FRAILTY (THE PREDYCI STUDY)

4. T.04.8: IBD PATIENTS SHOW WORRYING LEVELS OF SELF-REPORTED PHYSICAL INACTIVITY AS MEASURED BY THE INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE INDEPENDENTLY OF DISEASE ACTIVITY AND IBD PHENOTYPE: RESULTS FROM THE EXTENDED “BE-FIT-IBD” CROSS-SECTIONAL STUDY

5. P464 Could Chat Generative Pre-Trained Transformer (ChatGPT) be an AI-provided friend of the patients for frequently asked questions concerning their IBD management? An evidence- and guidelines-controlled textual analysis of AI-provided outputs

6. P1101 Patient-reported physical activity of IBD patients is of concern when weighed with the international physical activity questionnaire regardless of disease activity and IBD phenotype: barriers and facilitators emerged from the extended "BE-FIT-IBD" cross-sectional study

8. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

9. Development of a risk score to predict portal vein tumor thrombosis in patients with hepatocellular carcinoma

10. T.03.3 THE INFLUENCE OF SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV-2) LIFESTYLE CHANGES ON NON-ALCOHOLIC FATTY LIVER DISEASE EVOLUTION: A MATTER OF BODY COMPOSITION: A MULTICENTER CLINICAL STUDY

11. OC.08.5 THE ALPHA-GLUTATHIONE-S-TRANSFERASE (ALPHAGST) AND THE “METABOLIC ABNORMALITIES-AST/PLATELET RATIO-INFLAMMATION-ALPHAGST”(MARINA)-INDEX AS A NOVEL PREDICTIVE BIOMARKER AND COMPOSITE TOOL OF HEPATOPATHY PROGRESSION IN PATIENTS WITH MAFLD

14. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort

15. From "MAFLD" to "MASLD": was this revolution worth it? A head-to-head real-life comparison of MAFLD and MASLD criteria in estimating liver disease worsening risk in lean and not-lean steatotic patients.

16. Multidisciplinary management combining hepatologist counseling, cognitive/behavioral therapy, and nutritional support significantly improves clinical outcomes of Metabolic dysfunction-associated Steatotic Liver Disease (MASLD) patients.

17. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

18. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

21. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

22. Sarcopenia, malnutrition, and pruritus: a cholestasis-related "Cerberus" severely impacting the quality of life in patients with Primary Biliary Cholangitis (PBC). Is the systemic oxidative stress imbalance the driver? A preliminary observation.

23. Spleen area affects the predictive performance for decompensation of the platelet count-based non-invasive tools in MASLD-related cirrhosis: a preliminary observation.

24. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

25. Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort

26. Optimization of hepatitis C virus screening strategies by birth cohort in Italy

27. AF.90 RISK FACTORS FOR LIVER DECOMPENSATION AND HCC IN HCV-CIRRHOTIC PATIENTS AFTER DAAS: A MULTICENTER PROSPECTIVE STUDY

30. Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology

31. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

34. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

35. Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)

36. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

37. T06.01.16 EVALUATION OF THE EFFECT DERIVED FROM SILYBIN WITH VITAMIN D AND 3 VITAMIN E ADMINISTRATION ON CLINICAL, METABOLIC, ENDOTHELIAL 4 DYSFUNCTION, OXIDATIVE STRESS PARAMETERS AND SEROLOGICAL WORSENING 5 MARKERS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS

38. T02.01.9 EFFICACY OF 14-DAY CONCOMITANT THERAPY IN THE ERADICATION OF H. PYLORI INFECTION: COMPARISON WITH 10-DAY CONCOMITANT THERAPY

39. T06.01.9 THE BISPHENOL A INDUCED WORSENING OF NON-ALCOHOLIC FATTY LIVER DISEASE: A CLINICAL STRATEGY TO ANTAGONIZE THE PROGRESSION OF THE DISEASE

41. Corrigendum to 'Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV' [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)

42. Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice

43. Modelling cost-effectiveness and health gains of a 'universal' vs. 'prioritized' HCV treatment policy in a real-life cohort

44. L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV

45. P.07.22 HIGH RESOLUTION ANORECTAL MANOMETRY FOR DETERMINATION OF ANORECTAL FUNCTION IN ULCERATIVE COLITIS DURING DISEASE ACTIVITY AND AFTER REMISSION

48. Intrafamilial spread of Helicobacter pylori infection

49. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study

50. PITER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy

Catalog

Books, media, physical & digital resources